Clinical Trial Update: Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of CAL-101 in relapsed or refractory hematologic malignancies has completed, evaluating safety and preliminary activity in CLL, No…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAL-101 (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Status: COMPLETED